Sunitinib malate is a novel, molecularly targeted therapeutic agent, recently approved for the treatment of metastatic renal cell carcinoma (RCC) and gastrointestinal stromal tumors.1
Herein, we report the case of a 62-year-old male patient with metastatic RCC and severe necrotic foot syndrome (NFS) (Figure), a result of palmar-plantar erythrodysesthesia (PPE), with extensive tissue damage and aggravated by background diabetic vascular disease. The NFS developed predominantly in the patient's right foot 3 weeks after initiation of first-line therapy with sunitinib malate at a therapeutic regimen of 50 mg/d. Other common adverse effects of sunitinib2 (eg, anemia, hypertension, and dysgeusia) were also present and fully cleared after immediate discontinuation of the sunitinib treatment.
Guenova E, Weber HO, Voykov B, et al. Palmar-Plantar Erythrodysesthesia Secondary to Sunitinib Treatment Resulting in Necrotic Foot Syndrome Aggravated by Background Diabetic Vascular Disease. Arch Dermatol. 2008;144(8):1081–1082. doi:10.1001/archderm.144.8.1081
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: